Alvocidib prodrugs having increased bioavailability
US10562925B2 · kind B2 · utility
8Cited by
94References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 19, 2019 |
| Grant date | Feb 18, 2020 |
| Priority date | — |
| Expiry date | Feb 19, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(═O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.